236 related articles for article (PubMed ID: 29124519)
1. Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms.
Gajate P; Alonso-Gordoa T; Martínez-Sáez O; Molina-Cerrillo J; Grande E
Clin Transl Oncol; 2018 May; 20(5):561-569. PubMed ID: 29124519
[TBL] [Abstract][Full Text] [Related]
2. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
3. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
[TBL] [Abstract][Full Text] [Related]
4. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
Wolin EM
Cancer Lett; 2013 Jul; 335(1):1-8. PubMed ID: 23419523
[TBL] [Abstract][Full Text] [Related]
5. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutic approaches and mechanisms in neuroendocrine tumors: the role of targeted agents.
Papaxoinis G; Syrigos K; Saif MW
Discov Med; 2016 May; 21(117):391-402. PubMed ID: 27355335
[TBL] [Abstract][Full Text] [Related]
7. STK33 Promotes the Growth and Progression of Human Pancreatic Neuroendocrine Tumour via Activation of the PI3K/AKT/mTOR Pathway.
Zhou B; Xiang J; Zhan C; Liu J; Yan S
Neuroendocrinology; 2020; 110(3-4):307-320. PubMed ID: 31261148
[TBL] [Abstract][Full Text] [Related]
8. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
Mabuchi S; Kuroda H; Takahashi R; Sasano T
Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
[TBL] [Abstract][Full Text] [Related]
9. Hedgehog inhibitor sonidegib potentiates
Spetz J; Langen B; Rudqvist N; Parris TZ; Helou K; Nilsson O; Forssell-Aronsson E
BMC Cancer; 2017 Aug; 17(1):528. PubMed ID: 28789624
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
11. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
van der Ploeg P; Uittenboogaard A; Thijs AMJ; Westgeest HM; Boere IA; Lambrechts S; van de Stolpe A; Bekkers RLM; Piek JMJ
Gynecol Oncol; 2021 Nov; 163(2):433-444. PubMed ID: 34253390
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials.
Li X; Dai D; Chen B; Tang H; Xie X; Wei W
PLoS One; 2018; 13(2):e0192464. PubMed ID: 29408858
[TBL] [Abstract][Full Text] [Related]
14. Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors.
Beyens M; Vandamme T; Peeters M; Van Camp G; Op de Beeck K
Endocr Relat Cancer; 2019 Mar; 26(3):R109-R130. PubMed ID: 32022503
[TBL] [Abstract][Full Text] [Related]
15. The Potential Value of the PI3K/Akt/mTOR Signaling Pathway for Assessing Prognosis in Cervical Cancer and as a Target for Therapy.
Bahrami A; Hasanzadeh M; Hassanian SM; ShahidSales S; Ghayour-Mobarhan M; Ferns GA; Avan A
J Cell Biochem; 2017 Dec; 118(12):4163-4169. PubMed ID: 28475243
[TBL] [Abstract][Full Text] [Related]
16. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Bitting RL; Armstrong AJ
Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
[TBL] [Abstract][Full Text] [Related]
17. Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy.
Xu Z; Han X; Ou D; Liu T; Li Z; Jiang G; Liu J; Zhang J
Appl Microbiol Biotechnol; 2020 Jan; 104(2):575-587. PubMed ID: 31832711
[TBL] [Abstract][Full Text] [Related]
18. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
[TBL] [Abstract][Full Text] [Related]
19. PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms.
Briest F; Grabowski P
Theranostics; 2014; 4(4):336-65. PubMed ID: 24578720
[TBL] [Abstract][Full Text] [Related]
20. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Bartalucci N; Guglielmelli P; Vannucchi AM
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S307-9. PubMed ID: 24290217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]